JAPANESE - Skin Toxicity Evaluation Protocol With Panitumumab as 3rd line treatment for Colorectal Cancer(J-STEPP),(HGCSG1001)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Acronyms J-STEPP
- 06 Jun 2017 Results from STEPP and J-STEPP studies, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 18 Jan 2014 Results presented at the 2014 Gastrointestinal Cancers Symposium.